A Randomised, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Male Volunteers.

Trial Profile

A Randomised, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Repaglinide/metformin (Primary) ; Metformin; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 09 Dec 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov
    • 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 31 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top